Meihua International Medical Technologies Co., Ltd.

Company Overview

Business Model: Meihua International Medical Technologies Co., Ltd. specializes in the research, development, manufacturing, and sales of Class I, Class II, and Class III disposable medical devices. The Company operates through its subsidiaries in mainland China and Hong Kong, providing a "one-stop solution" to customers by offering both its own branded products and reselling qualified products sourced from other manufacturers. Primary revenue is generated from these manufacturing and resale activities.

Market Position: Meihua International Medical Technologies Co., Ltd. is a leading enterprise in China's medical consumables industry with over 30 years of operating history. The Company holds a strong regional position in Touqiao Town, Yangzhou City, Jiangsu Province, PRC, accounting for approximately 12% of the total revenues generated from all medical device manufacturers in the town. In 2024, its total sales exceeded RMB700 million (approximately $96 million) across more than 10,000 product types, significantly surpassing other local competitors. The Company's competitive strengths include cost-effective methods, an extensive distribution network, geographical advantages in a medical device manufacturing hub, economies of scale and automation, adherence to high-quality standards (ISO 13485, CE certification, FDA registration for over 20 Class I products), market-driven research and development, and an experienced management team.

Recent Strategic Developments:

• Initial Public Offering (IPO): Completed its IPO on February 18, 2022, raising approximately $34.58 million in net proceeds.
• New Subsidiary Establishment: Established Hainan Ruiying Technology Co. Ltd. on October 25, 2023, with Jiangsu Huadong Medical Device Industrial Co., Ltd. holding a 51% equity interest. This subsidiary is intended to serve as a trading and import-export company focused on introducing new medical technology, devices, and equipment.
• Deconsolidation of Subsidiary: On February 26, 2024, the Company deconsolidated Hainan Guoxie Technology Group Co. Ltd. after transferring 45% of its equity interest from Kang Fu International Medical Co., Limited to Jiangsu Huadong Medical Device Industrial Co., Ltd. and selling the remaining 10% to Yangzhou Boxin Medical Equipment Co., Ltd. for $637,940.
• Convertible Notes and Warrants Issuance: Entered into a securities purchase agreement on December 27, 2023, for the sale of up to $50.50 million in convertible notes and warrants. The initial closing on January 2, 2024, involved $6 million in notes. An amendment on December 26, 2024, limited the agreement to this single closing.
• Share Repurchase Plan: The board of directors approved a share repurchase plan on June 26, 2024, authorizing the repurchase of up to $3 million of outstanding Ordinary Shares. Between July 17, 2024, and August 14, 2024, the Company repurchased 232,098 shares for $200,000.
• Production Capacity Expansion: Completed construction of a 2,550 square meter new factory in 2022 at a cost of approximately $1.2 million. By 2023, 10 new production lines were installed at a cost of approximately $2.8 million, dedicated to producing medical and civil non-woven products for outbreak prevention, including masks, protective clothing, testing papers, and minimally invasive high-value consumables.

Geographic Footprint: Meihua International Medical Technologies Co., Ltd.'s primary operational regions are in mainland China, with its headquarters and manufacturing facilities located in Touqiao Town, Yangzhou City, Jiangsu Province, PRC. The Company's products are exported to over 30 countries across Europe, North America, South America, Asia, Africa, and Oceania. The Company is subject to regulatory frameworks in the PRC, Hong Kong, Cayman Islands, and complies with U.S. FDA registration and European CE certification requirements.

Cross-Border Operations: Meihua International Medical Technologies Co., Ltd. is a Cayman Islands holding company. Its direct subsidiary, Kang Fu International Medical Co., Limited, is based in Hong Kong. Operations are conducted through indirect subsidiaries in mainland China: Yangzhou Huada Medical Device Co., Ltd., Jiangsu Yada Technology Group Co., Ltd., Jiangsu Huadong Medical Device Industrial Co., Ltd., and Hainan Ruiying Technology Co. Ltd. (51% owned by Jiangsu Huadong Medical Device Industrial Co., Ltd.). Cash flows from Meihua International Medical Technologies Co., Ltd. to Kang Fu International Medical Co., Limited, and then to the PRC subsidiaries. Dividends are distributed in the reverse direction. The Company is subject to PRC regulations concerning dividend distribution, capital controls, foreign exchange, and overseas listings, including CSRC filing requirements for subsequent offerings. Dividends from PRC subsidiaries to the Hong Kong subsidiary may be subject to a 10% withholding tax, potentially reduced to 5% under a tax treaty, but this is not assured.

Financial Performance

Revenue Analysis

Profitability Metrics:

• Gross Margin: 34.36% (2024); 34.19% (2023)
• Operating Margin: 14.77% (2024); 15.11% (2023)
• Net Margin: 11.18% (2024); 11.94% (2023)

Investment in Growth:

• R&D Expenditure: $3,456,098 (3.57% of revenue) in 2024; $2,753,315 (2.83% of revenue) in 2023.
• Capital Expenditures: $133,550 for property, plant and equipment in 2024; $1,182,699 for property, plant and equipment and $3,503,883 for intangible assets in 2023.
• Strategic Investments: $4,864,016 in long-term investments and $17,290,577 in advances to related parties in 2024. In 2023, $9,179,624 in deposits to a related party for a pre-investment in Jiangsu Guomai Medical Equipment Co., Ltd.

Currency Impact Analysis:

• Foreign exchange impact on revenue and earnings: The Company recognized a currency exchange loss of $380,254 in 2024, compared to a gain of $153,440 in 2023. Unrealized foreign currency translation adjustments resulted in a loss of $4,271,912 in 2024 and $3,432,299 in 2023.
• Hedging strategies and effectiveness: Meihua International Medical Technologies Co., Ltd. does not hedge against currency risk.
• Functional currency considerations: The Company's reporting currency is USD. The functional currency of Kang Fu International Medical Co., Limited is HKD, while other PRC subsidiaries use RMB. The RMB depreciated by 2.8% against the USD in 2024 and 2.9% in 2023.

Business Segment Analysis

Medical Devices (Single Operating Segment)

Financial Performance:

• Revenue: $96,909,642 (-0.19% YoY) in 2024; $97,098,915 (-6.05% YoY) in 2023.
• Operating Margin: 14.77% in 2024.
• Key Growth Drivers: The Company's growth is driven by its capacity expansion, deep understanding of target markets, and strong relationships with customers, distributors, independent sales agents, and suppliers. Strategic initiatives include expanding its sales network and product offerings.

Product Portfolio:

• Major product lines and services within segment: The Company manufactures and sells Class I, II, and III disposable medical devices under its own brands, and resells sourced disposable medical devices from other manufacturers. Its portfolio includes 1,727 products, with 1,722 for domestic sales and 5 for overseas sales. Key products include disposable ID bracelets, disposable woman’s examination kits, disposable medical brushes, pharmaceutical packaging materials (LDPE eye drop bottles, HDPE tablet bottles), and various medical kits and tubes.
• New product launches or major updates: Ongoing R&D efforts focus on developing new products and enhancing existing ones, including a collaboration agreement for a patented tracheal tube kit.

Market Dynamics:

• Competitive positioning within segment: Meihua International Medical Technologies Co., Ltd. is a leading player in China's medical consumables industry, particularly strong in Touqiao Town, Yangzhou City, Jiangsu Province, PRC. It competes with numerous domestic and international companies, some with greater resources. The Company differentiates itself through its one-stop service model and cost advantages from economies of scale and automation.
• Key customer types and regional market trends: Customers include direct end-users (hospitals, pharmacies, medical institutions), domestic distributors, and export distributors. Domestic sales account for the vast majority of revenue (99.96% in 2024).
• Regulatory environment by jurisdiction: The Company operates under extensive PRC government regulation, requiring production and operation licenses, and registration/filing certificates for medical devices. It holds international CE certification and ISO 13485 system certification, and has FDA registration for over 20 Class I products.

Geographic Revenue Distribution:

• PRC (Domestic Sales): $96,870,000 (99.96% of segment revenue) in 2024, representing a 0.26% increase from 2023.
• International Sales: $38,764 (0.04% of segment revenue) in 2024, representing a 92.01% decrease from 2023. Products are exported to over 30 countries across Europe, North America, South America, Asia, Africa, and Oceania.
• Growth Markets: The Company aims to expand its geographic reach with new distribution channels both within China and overseas.

International Operations & Geographic Analysis

Revenue by Geography:

International Business Structure:

• Subsidiaries: Meihua International Medical Technologies Co., Ltd. (Cayman Islands holding company) directly owns Kang Fu International Medical Co., Limited (Hong Kong). Kang Fu International Medical Co., Limited wholly owns Yangzhou Huada Medical Device Co., Ltd., which wholly owns Jiangsu Yada Technology Group Co., Ltd., which wholly owns Jiangsu Huadong Medical Device Industrial Co., Ltd. Jiangsu Huadong Medical Device Industrial Co., Ltd. owns 51% of Hainan Ruiying Technology Co. Ltd.
• Joint Ventures: Not explicitly mentioned as JVs, but Hainan Ruiying Technology Co. Ltd. is a partially owned subsidiary.
• Licensing Agreements: The Company has a collaboration agreement with a patent owner for a tracheal tube kit, authorizing development and medical device registration, with a 25% after-tax profit-sharing arrangement.

Cross-Border Trade:

• Export Markets: Primary export destinations include over 30 countries in Europe, North America, South America, Asia, Africa, and Oceania, facilitated by 373 exporting distributors.
• Import Dependencies: Raw materials and products for resale are primarily sourced from certified suppliers and manufacturers within China, particularly in Touqiao Town. No significant import dependencies from outside China are explicitly detailed.
• Transfer Pricing: The filing does not provide specific details on transfer pricing policies or inter-company transactions beyond general tax risks.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: The Company repurchased 232,098 Ordinary Shares for $200,000 between July 17, 2024, and August 14, 2024, as part of a board-approved plan to repurchase up to $3 million of outstanding Ordinary Shares.
• Dividend Payments: Meihua International Medical Technologies Co., Ltd. has not paid any cash dividends to date and intends to retain available funds and future earnings to finance business development and growth.
• Dividend Yield: Not applicable, as no dividends have been paid.
• Future Capital Return Commitments: The Company has an authorized share repurchase plan of up to $3 million.

Balance Sheet Position:

• Cash and Equivalents: $17,288,952 as of December 31, 2024, including $1,328,895 in restricted cash.
• Total Debt: $7,945,966 in short-term bank borrowings as of December 31, 2024.
• Net Cash Position: $9,342,986 as of December 31, 2024.
• Credit Rating: Not disclosed in the filing.
• Debt Maturity Profile: Short-term bank borrowings mature within one year, with interest rates ranging from 2.42% to 3.45%. These loans are secured by the Company's assets and guaranteed by major shareholders and a subsidiary.

Cash Flow Generation:

• Operating Cash Flow: $14,636,805 in 2024.
• Free Cash Flow: Approximately $14,503,255 in 2024 (Operating Cash Flow of $14,636,805 minus Capital Expenditures of $133,550).
• Cash Conversion Metrics: Not explicitly detailed in the filing.

Currency Management:

• Cash holdings by major currencies: Substantially all cash is held in major financial institutions in Hong Kong and mainland China. The functional currency of Kang Fu International Medical Co., Limited is HKD, and for other PRC subsidiaries, it is RMB.
• Natural hedging through operational diversification: Not explicitly detailed.
• Financial hedging instruments and strategies: The Company does not hedge against currency risk.

Operational Excellence

Production & Service Model: Meihua International Medical Technologies Co., Ltd. employs a hybrid production model, combining in-house manufacturing at its facilities in Yangzhou, Jiangsu Province, PRC, with outsourcing to third-party manufacturers. All in-house production occurs in dust-free purification workshops and undergoes sterilization. The Company provides a "one-stop solution" service, fulfilling diverse customer orders by integrating its own branded products with qualified products sourced from other manufacturers, all subject to stringent quality control.

Global Supply Chain Architecture: Key Suppliers & Partners:

• Raw Material Suppliers: Numerous certified and qualified suppliers in China provide essential raw materials such as rubber, chemical PE, polyethylene, polypropylene, nylon, and non-woven fabrics.
• Manufacturing Partners: The Company outsources semi-finished product processing to local consigned manufacturers in Touqiao Town, expanding capacity and improving efficiency.
• Technology Partners: Collaborates with universities, hospitals, and medical institutions for research and development.
• Top Suppliers (2024): Yangzhou Tianyi Medical Device Co., Ltd. (13.73% of total purchases), Yangzhou Xiaguang Medical Device Co., Ltd. (9.14%), and Yangzhou Jiangzhou Medical Device Co., Ltd. (9.05%).

Facility Network:

• Manufacturing: Operates 12 purification plants covering approximately 110,352 square feet (10,252 square meters) in Yangzhou, Jiangsu Province, PRC. A new 2,550 square meter factory, completed in 2022, houses 10 production lines for exporting products.
• Research & Development: Maintains an R&D department with 69 employees at its PRC operating subsidiaries, focusing on polymer materials, medicine, molds, and mechanical automation.
• Distribution: Utilizes a direct sales force of 81 employees, 4,859 independent sales agents, 3,926 domestic distributors, and 373 exporting distributors.

Operational Metrics:

• Capacity utilization: While specific metrics are not disclosed, the Company notes that its production capacity for certain pandemic prevention products is limited.
• Efficiency measures: Equipment retrofitting and automation have been implemented to enhance production efficiency.
• Quality indicators: The Company maintains ISO 13485:2016 certification and European Union’s CE certification, and has FDA registration for over 20 Class I products. Annual quality targets are set, with monthly follow-ups and quarterly evaluations.

Market Access & Customer Relationships

Go-to-Market Strategy: Distribution Channels:

• Direct Sales: The Company employs a direct sales force of 81 individuals, serving approximately 560 domestic customers, including hospitals and medical institutions.
• Channel Partners: Leverages a broad network of 4,859 independent sales agents across China and 3,926 domestic distributors covering 33 provincial-level administrative regions, reaching approximately 5,992 domestic customers. For international markets, 373 exporting distributors serve customers in over 30 countries, estimated to be about 1,119 direct and indirect customer relationships.
• Digital Platforms: Not explicitly mentioned in the filing.

Customer Portfolio: Enterprise Customers:

• Tier 1 Clients: The top five customers contributed approximately 41.90% of total revenue in 2024 (46.31% in 2023 and 56.53% in 2022). The top two customers in 2024 were domestic distributors, accounting for 12.77% and 8.64% of revenues, respectively.
• Strategic Partnerships: The Company has established long-term cooperative relationships with well-known foreign medical equipment brand companies.
• Customer Concentration: The significant revenue contribution from top customers indicates a degree of customer concentration risk.

Regional Market Penetration:

• PRC: Domestic sales constitute 99.96% of total revenue in 2024, with products distributed across all regions of the PRC.
• International: International sales accounted for 0.04% of total revenue in 2024, with products exported to over 30 countries across Europe, North America, South America, Asia, Africa, and Oceania.
• Growth Markets: The Company is focused on expanding its customer base and brand recognition both within the PRC and internationally.

Competitive Intelligence

Global Market Structure & Dynamics

Industry Characteristics: The medical device industry is intensely competitive, characterized by rapid technological change and frequent new product introductions. It involves thousands of companies globally and domestically. Key trends include increasing outsourcing of design and manufacturing, and in China, the "two-invoice system" and centralized procurement models are shortening distribution channels and exerting downward pressure on prices. Touqiao Town, Yangzhou City, Jiangsu Province, PRC, is a significant medical device manufacturing hub.

Competitive Positioning Matrix:

Direct Competitors

Primary Competitors:

• Shandong Weigao Group Medical Polymer Co., Limited: A major player in single-use medical devices, with sales primarily in the PRC and active international expansion.
• Jiangxi Hongda Medical Equipment Group Ltd.: Specializes in sterile medical devices, holding a significant market share in China and serving as a major international supplier.
• Henan Tuoren Medical Device Co., Ltd.: A healthcare solutions provider with a broad product range, selling to over 70 countries and having international subsidiaries.
• Allmed Medical Products Co., Ltd.: The largest OEM manufacturer and exporter of wound care products in China, with a more limited product scope compared to Meihua International Medical Technologies Co., Ltd.
• Jiangxi Sanxin Medtec Co., Ltd.: A listed company focused on R&D, manufacturing, and marketing of medical devices, with extensive domestic and international sales.
• Jiangxi 3L Products Group Co., Ltd.: Combines research, production, and marketing of macromolecular products, with a strong domestic market share in surgical towels and international trade.

Regional Competitive Dynamics: Within Touqiao Town, Meihua International Medical Technologies Co., Ltd. views other local companies more as partners due to the vast market and their complementary product offerings. The Company engages in mutual supply and procurement with these local enterprises. Meihua International Medical Technologies Co., Ltd. also cooperates with larger national competitors like Shandong Weigao Group Medical Polymer Co., Limited and Henan Tuoren Medical Device Co., Ltd. by distributing each other's products in different regions. An industry alliance fosters collaboration and market development among local companies.

Risk Assessment Framework

Strategic & Market Risks

Global Market Dynamics:

• Economic Recessions: Deterioration in the global economic environment could adversely impact operating results and long-term growth by reducing customer discretionary spending and demand for products.
• Technology Disruption: The rapid pace of technological change in the medical device market poses a risk that competitors' innovations could render the Company's products obsolete.
• Customer Concentration: A significant portion of revenue is derived from a few top customers (41.90% from the top five in 2024), creating a risk if these customers reduce orders or shift to competitors.
• U.S.-China Trade Tensions: Imposition of tariffs and trade restrictions could increase raw material costs, disrupt manufacturing, and negatively affect the Company's competitiveness and profitability, despite international sales being a relatively small portion of total revenue.

Operational & Execution Risks

Global Supply Chain Vulnerabilities:

• Supplier Dependency: The Company lacks long-term contracts with its numerous suppliers, meaning they could reduce quantities or cease sales at any time, potentially disrupting operations.
• Regional Disruptions: Events such as pandemics, epidemics, natural disasters, terrorist activities, or political unrest could disrupt delivery and operations.
• Trade Restrictions: Changes in foreign regulations, export duties, taxation, and import/export limitations could increase operational costs or restrict the Company's ability to conduct international business.

Financial & Regulatory Risks

Currency & Financial Risks:

• Foreign Exchange: Fluctuations in the Renminbi (RMB) against the U.S. dollar can materially affect reported financial results and investment value, particularly when converting USD to RMB for operations or RMB to USD for dividends. The Company does not employ hedging strategies.
• Interest Rate Risk: The Company is not currently exposed to interest rate risk as its interest-bearing debt carries a fixed rate.
• Credit & Liquidity: The Company faces a risk of uncollectible accounts receivable, with a balance of $78,660,700 in 2024.
• IPO Fraud: The Company believes it was defrauded of over $10 million in connection with its 2022 IPO by Tai He International Group Limited and Shengang Securities Company Limited, resulting in a $4.8 million deposit write-off and a $2.3 million service fee expense in 2022. This situation could lead to potential shareholder litigation and/or SEC enforcement actions.
• Legal Proceedings: The Company is involved in a legal proceeding (Zhu Cheng v. Jiangsu Yada Technology Group Co., Ltd. et al.) claiming $2.3 million plus interest, with a court ruling for Jiangsu Yada Technology Group Co., Ltd. to pay RMB 17 million plus interest. The Company has appealed and provided a restricted deposit of approximately $1.3 million.

Regulatory & Compliance Risks:

• Multi-Jurisdictional Compliance: Operations in the PRC are subject to complex and rapidly evolving laws and regulations, with significant government oversight and discretion.
• Trade Regulations: Changes in domestic industry policies, such as the "two-invoice system" and centralized procurement, could impact operations and profitability.
• Tax Regulations: Potential classification as a PRC resident enterprise could result in unfavorable tax consequences for the Company and its non-PRC shareholders, including a 25% enterprise income tax rate on global income and a 10% withholding tax on dividends. Uncertainties also exist regarding indirect transfers of equity interests.
• Cybersecurity & Data Protection: Non-compliance with evolving PRC cybersecurity and data protection laws could lead to fines, sanctions, or reputational damage, although the Company believes its business is generally outside the scope of current strict data regulations.
• Overseas Listing Regulations: Uncertainty exists regarding future PRC government permissions or approvals required for overseas listings, particularly under the CSRC's New Overseas Listing Rules.
• HFCAA: There is a risk of delisting from Nasdaq if the PCAOB is unable to inspect the Company's auditor for two consecutive years, although the current auditor, Kreit & Chiu CPA LLP, is U.S.-based and subject to PCAOB inspection.
• Labor Laws: Non-compliance with PRC labor laws regarding contracts, social benefits, and minimum wages could result in fines or additional compensation.
• Environmental Laws: The Company is subject to PRC environmental laws concerning wastewater, exhaust gas, solid waste, and equipment noise. Non-compliance could lead to fines or production suspension.
• Medical Device Licenses: Failure to timely renew medical device licenses or registration certificates could adversely affect the Company's reputation and operations.

Geopolitical & External Risks

Country-Specific Risks:

• Political Risk: The PRC government's significant oversight and discretion could lead to intervention in the Company's operations at any time.
• Economic Risk: Changes in the PRC's economic, political, or social conditions could have a material adverse effect on the Company's business.
• Regulatory Changes: The rapidly evolving PRC legal system, with its uncertain interpretation and enforcement of laws, poses a risk to the Company's operations.

Innovation & Technology Leadership

Research & Development Focus: Global R&D Network:

• R&D Department: Meihua International Medical Technologies Co., Ltd. maintains an R&D department with 69 employees, representing 11.15% of its total workforce.
• R&D Centers: R&D activities are primarily conducted at the Company's operating subsidiaries in the PRC.
• Focus Areas: The R&D team possesses expertise in polymer materials, medicine, molds, and mechanical automation.
• Innovation Pipeline: The Company adheres to a market-oriented R&D approach, actively collaborating with universities, hospitals, medical institutions, distributors, and independent sales agents to align R&D efforts with real market demand. This includes acquiring patents for innovative products and continuously upgrading existing offerings.

Intellectual Property Portfolio:

• Patent Strategy: As of the date of the Annual Report, the Company holds 27 registered patents in China, encompassing invention and utility model patents. These patents are foundational for future research and the planned development of new products, rather than relating to its current top 20 mature products.
• Licensing Programs: The Company is currently engaged in a collaboration agreement to develop and register a patented tracheal tube kit for production and sale. This agreement includes a 25% after-tax profit-sharing arrangement with the patent owner.
• IP Litigation: Historically, Jiangsu Huadong Medical Device Industrial Co., Ltd. was involved in a patent infringement case that has since been settled.

Technology Partnerships: The Company forms strategic alliances and research collaborations with universities, hospitals, medical institutions, distributors, and independent sales agents to inform its R&D orientation and gather customer feedback, ensuring continuous product improvement.

Leadership & Governance

Executive Leadership Team

International Management Structure: The Company's management team includes executives with diverse backgrounds, including international financial market experience (Xin Wang) and local industry expertise (Yongjun Liu, Xiaoming E, Wenzhang Jia). Specific details on regional leadership and the balance between local management autonomy and centralized oversight are not explicitly detailed in the filing.

Board Composition: The board of directors includes three independent directors: Wenzhang Jia, Xiaoming E, and Huijuan Zhao. All meet the independence requirements of the Nasdaq Stock Market and Rule 10A-3 under the Exchange Act. Wenzhang Jia is designated as an "audit committee financial expert." The board maintains an Audit Committee (chaired by Wenzhang Jia), a Compensation Committee (chaired by Huijuan Zhao), and a Nominating Committee (chaired by Huijuan Zhao). Yongjun Liu, as the controlling shareholder, holds approximately 50.0% of the total voting power, classifying the Company as a "controlled company" under Nasdaq rules, though it does not currently intend to rely on the associated exemptions. The Company has elected to follow certain Cayman Islands home country practices in lieu of specific Nasdaq corporate governance requirements, such as those related to annual general meetings, director elections, and shareholder approval for certain share issuances.

Regulatory Environment & Compliance

Multi-Jurisdictional Regulatory Framework: Primary Regulatory Environments:

• PRC: Meihua International Medical Technologies Co., Ltd.'s operations are extensively regulated by PRC laws and regulations, including those governing medical device production and sales (requiring production licenses, operation licenses, and registration/filing certificates for Class I, II, and III medical devices). The Company is also subject to environmental protection laws, customer protection laws, labor laws, enterprise income tax laws, value-added tax laws, foreign investment laws, cybersecurity and data protection laws (Cyber Security Law, Data Security Law, Personal Information Protection Law), and regulations concerning mergers and acquisitions (M&A Rules) and foreign exchange (SAFE regulations).
• Hong Kong: Kang Fu International Medical Co., Limited, the Company's Hong Kong subsidiary, is subject to Hong Kong income tax, which applies a two-tiered profit tax rate regime (8.25% for the first HK$2 million of assessable profits and 16.5% for the remainder).
• U.S.: As a foreign private issuer listed on the Nasdaq Global Market, the Company is subject to the informational requirements of the Exchange Act and Nasdaq listing rules. It faces potential risks related to the Holding Foreign Companies Accountable Act (HFCAA), which could lead to delisting if its auditor is not fully inspected by the PCAOB for two consecutive years.

Cross-Border Compliance:

• Export Controls: The Company must comply with requirements for Medical Device Product Export Sales Certificates for certain importing countries.
• Sanctions Compliance: While not explicitly detailed, the Company's operations are subject to general PRC regulatory risks, including potential trade restrictions.
• Anti-Corruption: The Company has established an internal control system to prevent and mitigate improper business practices and unauthorized rebates in medical device sales transactions.

International Tax Strategy:

• Transfer Pricing: The filing does not provide specific details on the Company's transfer pricing policies or documentation requirements.
• Tax Treaties: Dividends paid by PRC subsidiaries to the Hong Kong subsidiary may be subject to a reduced withholding tax rate of 5% under the tax agreement between Mainland China and Hong Kong, but the application of this reduced rate is not guaranteed and is subject to determination by tax authorities.
• BEPS Compliance: The filing does not provide specific details on the Company's compliance with Base Erosion and Profit Shifting (BEPS) regulations.

Environmental & Social Impact

Global Sustainability Strategy: Environmental Commitments:

• Climate Strategy: The Company's manufacturing processes generate wastewater, exhaust gas, solid waste, and equipment noise. It has implemented a systematic environmental protection management system to treat these outputs in accordance with national requirements.
• Carbon Neutrality: Not explicitly detailed in the filing.
• Renewable Energy: Not explicitly detailed in the filing.
• Regional Sustainability Initiatives: The Company's waste discharge is in compliance with local laws and regulations. It passed an environmental inspection and evaluation by the Environmental Protection Bureau of Yangzhou Guangling District in 2020. Waste discharge fees were $4,415 in 2024, $5,105 in 2023, and $4,384 in 2022. The Company anticipates increased environmental protection spending with future expansion projects.
• Supply Chain: Not explicitly detailed beyond general compliance.

Social Impact by Region:

• Community Investment: The Company's founder, Yongjun Liu, actively participates in philanthropic activities, including road reconstruction, donations to the Red Cross Society, nursing home reconstruction, poverty alleviation, and student aid.
• Labor Standards: The Company participates in PRC government-mandated employee benefit contribution plans, covering pension, medical insurance, unemployment insurance, maternity insurance, on-the-job injury insurance, and housing funds. It reports maintaining good working relationships with employees and has not experienced any material labor disputes.

Currency Management & Financial Strategy

Multi-Currency Operations: Currency Exposure:

Hedging Strategies:

• Transaction Hedging: The Company does not engage in transaction hedging.
• Translation Hedging: The Company does not engage in translation hedging.
• Economic Hedging: The Company does not engage in economic hedging. The Company's functional currency is RMB, and its financial statements are presented in USD. Fluctuations in the RMB/USD exchange rate can affect reported financial results. The RMB depreciated by 2.8% in 2024 and 2.9% in 2023 against the U.S. dollar.